A study in the journal Oncogene found that a class of drugs called BET bromodomain inhibitors can effectively treat primary effusion lymphoma, a rare and aggressive blood cancer. The disease is caused by infection with Kaposi's sarcoma-associated herpes virus and is most commonly seen among patients with HIV. Inhibitors targeting the BRD4 protein halted the growth of PEL cells in laboratory and animal tests.

Related Summaries